


Supplementary Content

| | | |
|-----------------|--|----|
| Figure 1 | Development of propensity score matched subpopulations | 2 |
| Table 1 | STrengthening the Reporting of OBservational studies in Epidemiologychecklist of items for reporting | 3 |
| Table 2 | List of databases held at the Institute for Clinical Evaluative Sciences | 5 |
| Table 3 | Coding definitions for co-morbid conditions | 7 |
| Table 4 | Diagnostic codes for health care utilization characteristics | 10 |
| Table 5 | Diagnostic codes for exclusion criteria | 12 |
| Table 6 | Diagnostic codes for outcome variables | 13 |
| Table 7 | Characteristics used to derive propensity scores | 14 |
| Table 8 | Definition and staging of acute kidney injury | 16 |
| Table 9 | Additional baseline characteristics of patients discharged home from the emergency department with acute kidney injury | 17 |
| Table 10 | Most common main diagnoses assigned by physicians to patients discharged home from the emergency department with acute kidney injury | 23 |
| Table 11 | Baselinecharacteristics of the acute kidney injury subpopulation before and after propensity score matching | 24 |
| Table 12 | Baselinecharacteristics of the discharge subpopulation before and after propensity score matching | 33 |
| | References for Supplementary Content | 42 |

Figure 1. Development of propensity score matched subpopulations



Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; ED, emergency department; eGFR, estimated glomerular filtration rate.

^a Matched 1:1 for ED disposition (discharge home versus admission to hospital) and AKI stage. The propensity score was derived from 92 characteristics (Supplemental Table 7).

^b Matched 1:1 for the presence of AKI and CKD stage. The propensity score was derived from 91 characteristics (Supplemental Table 7).

^c Patients were admitted to hospital for acute dialysis.

^d AKI staging according to 2012 Kidney Diseases: Improving Global Outcomes clinical practice guidelines (Supplemental Table 8).¹

^e CKD staging according to 2012 Kidney Diseases: Improving Global Outcomes clinical practice guidelines (in ml/min/1.73m²): eGFR ≥ 60 (no CKD or CKD stage 1 or 2); 45 ≤ eGFR < 60 (CKD stage 3a), 30 ≤ eGFR < 45 (CKD stage 3b); 15 ≤ eGFR < 30 (CKD stage 4); and eGFR < 15, but not on dialysis (CKD stage 5).²

Table 1. STrengthening the Reporting of OBservational studies in Epidemiology checklist of items for reporting³

| Section | Item no. | Recommendation | Reported ^a |
|------------------------------|----------|---|-----------------------|
| Title and abstract | | | |
| | 1a | Indicate the study's design with a commonly used term in the title or the abstract | 1 |
| | 1b | Provide in the abstract an informative and balanced summary of what was done and what was found | 2 |
| Introduction | | | |
| Background | 2 | Explain the scientific background and rationale for the investigation being reported | 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 4 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 5 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 5 |
| Participants | 6 | Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 6,7 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 5-9 |
| Data sources and measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5-9 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 8,9 |
| Study size | 10 | Explain how the study size was arrived at | 6-9 |
| Quantitative Variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 8,9 |
| Statistical methods | 12a | Describe all statistical methods, including those used to control for confounding | 8,9 |
| | 12b | Describe any methods used to examine subgroups and interactions | 8,9 |
| | 12c | Explain how missing data were addressed | 8,9 |
| | 12d | If applicable, explain how loss to follow-up was addressed | 8,9 |
| | 12e | Describe any sensitivity analyses ^b | N/A |
| Results | | | |
| Participants | 13a | Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 9-12,26 |

| | | | |
|--------------------------|-----|--|--------------------------------------|
| | 13b | Give reasons for non-participation at each stage | 9,10,25 |
| | 13c | Consider use of a flow diagram | Figure 1 |
| Descriptive data | 14a | Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders | 9-12, 26-29 |
| | 14b | Indicate number of participants with missing data for each variable of interest | 9,10 |
| | 14c | Summarise follow-up time (e.g., average and total amount) | 8,25, Figure 1 |
| Outcome data | 15 | Report numbers of outcome events or summary measures over time | 10-12, 30-32 |
| Main results | 16 | Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 10-12, 26-32 Supplemental Table 7 |
| | | Report category boundaries when continuous variables were categorized | 26-32 |
| | | If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 11,12,31,32 |
| Other analyses | 17 | Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses ^b | 11,12,31,32 |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 12 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | 14,15 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 12-15 |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results | 12,15 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 15-17 |

^aLocation of STrengthening the Reporting of OBServational studies in Epidemiology checklist items refer to the page numbers in the final manuscript submission.

^bAll analyses reported in study. No other sensitivity analyses were done.

Table 2. List of databases held at the Institute for Clinical Evaluative Sciences

| Data Source | Description | Study Purpose |
|---|--|--|
| Assistive Device Program | The Assistive Device Program database is operated by the Ministry of Health and Long-Term Care. It contains information on consumer-centered support to Ontario residents with long-term disabilities such as personalized assistive devices. | Estimation of health care costs |
| Client Agency Program Enrolment | The Client Agency Program Enrolment database accounts for the services provided by multi-disciplinary family health teams comprised of family physicians, nurses, and other allied healthcare professionals. | Estimation of health care costs |
| Continuing Care Reporting System | The Continuing Care Reporting System for chronic care database contains clinical and demographic information on residents receiving facility-based continuing care services, including hospital-based continuing care (complex continuing care, extended/chronic care) and residential care providing 24-hour nursing services (nursing home, home for the aged). | Estimation of health care costs |
| Cerner | Electronic health record database (Cerner, Missouri, USA) shared by 13 hospitals in Southwestern Ontario and contains both outpatient and inpatient laboratory test results for adults 40 years and older. | Cohort creation, stratification, description, exposure, and outcome |
| Canadian Institute for Health Information Discharge Abstract Database and National Ambulatory Care Reporting System | The Canadian Institute for Health Information Discharge Abstract Database and National Ambulatory Care Reporting System collect diagnostic and procedural variables for inpatient stays and ED visits, respectively. Diagnostic and inpatient procedural coding use the 10 th version of the Canadian Modified International Classification of Disease system 10 th Revision (after 2002). | Cohort creation, stratification, description, exposure, and outcome Estimation of health care costs |
| Dynacare (formerly known as Gamma-Dynacare Medical Laboratories) | Database that contains all outpatient laboratory test results from all Dynacare laboratory locations across Ontario since 2002. Dynacare is one of the three largest laboratory providers in Ontario and contains records on over 59 million tests each year. | Cohort creation, stratification, description, exposure, and outcome |
| Home Care Database | The Home Care Database, derived from either the Ontario Association of Community Care Access Centres or the Ministry of Health, contains information on individuals requiring any home care service provided by the province's Community Care Access Centres. | Estimation of health care costs |
| Institute for Clinical Evaluative Sciences Physician Database | The Institute for Clinical Evaluative Sciences Physician Database contains demographic, specialty, education, and practice information on all practicing physicians in Ontario. | Cohort description, and outcome |
| National Rehabilitation Reporting System | The National Rehabilitation Reporting System database collects, processes and analyzes adult inpatient rehabilitation services at the hospital, regional, and provincial/territorial levels. | Estimation of health care costs |
| Ontario Drug Benefits | The Ontario Drug Benefits database includes a wide range of outpatient prescription medications available to all Ontario citizens over the age of 65 and in specific circumstances for citizens under the age of 65. The error rate in the | Medication prescriptions Estimation of health care |

| | | |
|--|---|--|
| | Ontario Drug Benefits database is less than 1%. ⁴ | costs |
| Ontario Health Insurance Plan | The Ontario Health Insurance Plan database contains information on Ontario physician billing claims for medical services using fee and diagnosis codes outlined in the Ontario Health Insurance Plan Schedule of Benefits. These codes capture information on outpatient, inpatient, and laboratory services rendered to a patient. The sensitivity of information recorded in the Ontario Health Insurance Plan database is over 90% when diagnosis and procedural codes abstracted from the database are compared to the actual code recorded on the chart by the physician. ⁵ | Cohort creation, stratification, description, exposure, and outcome Estimation of health care costs |
| Ontario Mental Health Reporting System | The Ontario Mental Health Reporting System database collects data on patients in adult designated inpatient mental health beds, which includes beds in General, Provincial Psychiatric, and Specialty Psychiatric facilities. | Estimation of health care costs |
| Registered Persons Database | The Registered Persons Database captures demographic (sex, date of birth, postal code) and vital status information on all Ontario residents. Relative to the Canadian Institute for Health Information Discharge Abstract Database in-hospital death flag, the Registered Persons Database has a sensitivity of 94% and a positive predictive value of 100%. ⁶ | Cohort creation and outcome analyses |

Table 3. Coding definitions for co-morbid conditions

| Variable | Database | Code Set | Code |
|--|---|--|--|
| Abdominal aortic aneurysm repair | Canadian Institute for Health Information Discharge Abstract Database | Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures | 5024, 5034 |
| | | Canadian Classification of Health Interventions | 1KA76 |
| | Ontario Health Insurance Plan | Fee code | R802, R816, R817, R783, R784, R785, R814 |
| Atrial fibrillation or flutter | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 4273 |
| | | International Classification of Diseases 10 th Revision | I48 |
| Major cancer ^a | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 150, 154, 155, 157, 162, 174, 175, 185, 203, 204, 205, 206, 207, 208, 2303, 2304, 2307, 2330, 2312, 2334 |
| | | International Classification of Diseases 10 th Revision | 971, 980, 982, 984, 985, 986, 987, 988, 989, 990, 991, 993, C15, C18, C19, C20, C22, C25, C34, C50, C56, C61, C82, C83, C85, C91, C92, C93, C94, C95, D00, D010, D011, D012, D022, D075, D05 |
| | Ontario Health Insurance Plan | Diagnosis | 203, 204, 205, 206, 207, 208, 150, 154, 155, 157, 162, 174, 175, 183, 185 |
| Chronic liver disease | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 4561, 4562, 070, 5722, 5723, 5724, 5728, 573, 7824, V026, 571, 2750, 2751, 7891, 7895 |
| | | International Classification of Diseases 10 th Revision | B16, B17, B18, B19, I85, R17, R18, R160, R162, B942, Z225, E831, E830, K70, K713, K714, K715, K717, K721, K729, K73, K74, K753, K754, K758, K759, K76, K77 |
| | Ontario Health Insurance Plan | Diagnosis | 571, 573, 070 |
| | | Fee code | Z551, Z554 |
| Chronic obstructive pulmonary disease | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 491, 492, 496 |
| | | International Classification of Diseases 10 th Revision | J41, J43, J44 |
| Coronary artery disease (excluding angina) | Canadian Institute for Health Information Discharge Abstract Database | Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures | 4801, 4802, 4803, 4804, 4805, 481, 482, 483 |
| | | Canadian Classification of Health Interventions | 11J50, 11J76 |

| | | | |
|---------------------------|---|--|---|
| | | International Classification of Diseases 9 th Revision | 412, 410, 411 |
| | | International Classification of Diseases 10 th Revision | I21, I22, Z955, T822 |
| | Ontario Health Insurance Plan | Diagnosis | 410, 412 |
| | | Fee code | R741, R742, R743, G298, E646, E651, E652, E654, E655, Z434, Z448 |
| Dementia | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 2900, 2901, 2903, 2904, 2908, 2909, 2948, 2949, 3310, 3311, 3312, 2941, 797 |
| | | International Classification of Diseases 10 th Revision | F065, F066, F068, F069, F09, F00, F01, F02, F03, F051, G30, G31, R54 |
| | Ontario Health Insurance Plan | Diagnosis | 290, 331, 797 |
| Diabetes ^b | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 250 |
| | | International Classification of Diseases 10 th Revision | E10, E11, E13, E14 |
| | Ontario Health Insurance Plan | Diagnosis | 250 |
| | | Fee code | Q040, K029, K030, K045, K046 |
| Heart failure | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 425, 5184, 428, 514 |
| | | International Classification of Diseases 10 th Revision | I500, I501, I509, I255, J81 |
| | | Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures | 4961, 4962, 4963, 4964 |
| | | Canadian Classification of Health Interventions | 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 1HZ53SYFR |
| | Ontario Health Insurance Plan | Diagnosis | 428 |
| | | Fee code | R701, R702, Z429 |
| Hypertension ^b | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 401, 402, 403, 404, 405 |
| | | International Classification of Diseases 10 th Revision | I10, I11, I12, I13, I15 |
| | Ontario Health Insurance Plan | Diagnosis | 401, 402, 403 |
| Nephrolithiasis | Canadian Institute for Health Information | International Classification of Diseases 9 th Revision | 5920, 5921, 5929, 5940, 5941, 5942, 5948, 5949, 27411 |

| | | | |
|---|---|--|---|
| | Discharge Abstract Database | International Classification of Diseases 10 th Revision | N200, N201, N202, N209, N210, N211, N218, N219, N220, N228 |
| Osteoarthritis | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 715 |
| | | International Classification of Diseases 10 th Revision | M15, M16, M17, M18, M19, M47 |
| Parkinson's disease | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 332 |
| | | International Classification of Diseases 10 th Revision | G20, F023 |
| Peripheral vascular disease | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 4402, 4408, 4409, 5571, 4439, 444 |
| | | International Classification of Diseases 10 th Revision | I700, I702, I708, I709, I731, I738, I739, K551 |
| | | Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures | 5125, 5129, 5014, 5016, 5018, 5028, 5038, 5126, 5159 |
| | | Canadian Classification of Health Interventions | 1KA76, 1KA50, 1KE76, 1KG50, 1KG57, 1KG76MI, 1KG87, 1IA87LA, 1IB87LA, 1IC87LA, 1ID87LA, 1KA87LA, 1KE57 |
| | Ontario Health Insurance Plan | Fee code | R787, R780, R797, R804, R809, R875, R815, R936, R783, R784, R785, E626, R814, R786, R937, R860, R861, R855, R856, R933, R934, R791, E672, R794, R813, R867, E649 |
| Rheumatoid arthritis | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 714 |
| | | International Classification of Diseases 10 th Revision | M05, M06 |
| | Ontario Health Insurance Plan | Diagnosis | 714 |
| Cerebrovascular disease (stroke or transient ischemic attack) | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | 430, 431, 432, 4340, 4341, 4349, 435, 436, 3623 |
| | | International Classification of Diseases 10 th Revision | I62, I630, I631, I632, I633, I634, I635, I638, I639, I64, H341, I600, I601, I602, I603, I604, I605, I606, I607, I609, I61, G450, G451, G452, G453, G458, G459, H340 |

^aList of major cancers include lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovarian, and esophageal cancers.

^bMedications were not considered as not all patients have medication information available.

Table 4.Diagnostic codes for health care utilization characteristics

| Variable | Database | Code Set | Code |
|---|---|--|---|
| Family physician visit | Ontario Health Insurance Plan | Fee code | A001, A003, A004, A005, A006, A007, A008, A900, A901, A905, A911, A912, A967, K131, K132, K140, K141, K142, K143, K144, W003, W008, W121 |
| | Institute for Clinical Evaluative Sciences Physician Database | Main specialty | GP/FP |
| Internal medicine physician visit | Ontario Health Insurance Plan | Fee code | A135, C135 |
| | Institute for Clinical Evaluative Sciences Physician Database | Main specialty | INTERNAL MEDICINE |
| Nephrologist visit | Ontario Health Insurance Plan | Fee code | A135, A161, A163, A164, A165, A166, A168, C101, C138, G860, G323, G333, E083, C132, C135, C137, C139, H540, G325, G326, G860, G865, G866, G330, G331, G332, G861, G864 |
| | Institute for Clinical Evaluative Sciences Physician Database | Main specialty | NEPHROLOGY |
| Urology visit | Ontario Health Insurance Plan | Fee code | A355, A356, A353, A354, C355, C356, C353, C354 Z606, Z628, Z632, Z633, Z634, S655, S654 |
| | Institute for Clinical Evaluative Sciences Physician Database | Main specialty | UROLOGY |
| Coronary angiogram or revascularization | Canadian Institute for Health Information Discharge Abstract Database | Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures | 4892, 4893, 4894, 4895, 4896, 4897, 4898, 481, 482, 483, 480 |
| | | Canadian Classification of Health Interventions | 3IP10, 3IS10, 1IJ50, 1IJ26, 1IJ27, 1IJ57, 1IJ76, 1IJ57GQ, 1IJ54GQAZ |
| | Ontario Health Insurance Plan | Fee code | G297, G509, R741, R742, R743, E651, E652, E654, E646, G298, Z434, G262 |
| Computed tomography scan with contrast | Canadian Institute for Health Information Discharge Abstract Database | Canadian Classification of Health Interventions | 3AF20WC, 3AN20WC, 3CA20WC, 3DR20WC, 3EA20WC, 3EL20WC, 3ER20WC, 3EY20WC, 3FX20WC, 3FY20WC, 3GE20WC, 3GT20WC, 3GY20WC, 3ID20WC, 3IP20WC, 3JE20WC, 3JX20WC, 3JY20WC, 3KE20WC, 3KG20WC, 3KT20WC, 3NM20WC, 3OT20WC, 3PC20WC, 3PZ20WC, 3QT20WC, 3SC20WC, 3SF20WC, 3TZ20WC, 3VZ20WC, 3WZ20WC, 3YM20WC, 3ZZ20WC, 3FY20VZ, 3FY20VC |
| Echocardiogram | Canadian Institute for | Canadian Classification of | 0282 |

| | | | |
|----------------------------|---|--|--|
| | Health Information Discharge Abstract Database | Diagnostic, Therapeutic and Surgical Procedures | |
| | | Canadian Classification of Health Interventions | 3IP30 |
| | Ontario Health Insurance Plan | Fee code ^a | G560, G561, G562, G566, G567, G568, G570, G571, G572, G574, G575, G576, G577, G578, G581 |
| Cardiac stress test | Canadian Institute for Health Information Discharge Abstract Database | Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures | 0341, 0342, 0343, 0344, 0605 |
| | | Canadian Classification of Health Interventions | 2HZ08, 3IP70 |
| | Ontario Health Insurance Plan | Fee code | G315, G174, G111, G112, G319, G582, G583, G584, J607, J608, J807, J808, J809, J866, J609, J666 |
| Abdominal ultrasound | Ontario Health Insurance Plan | Fee code | J128, J135, J428, J435 |
| Kidney stone interventions | Ontario Health Insurance Plan | Fee code | Z630, Z628, E760, E761, Z624, Z627 |

^a G560, G561, G562, G566, G567, G568, G576 are no longer in the Ontario Health Insurance Plan fee schedule as of 2014/11

Table 5. Diagnostic codes for exclusion criteria

| Variable | Database | Code Set | Code |
|---------------------|---|--|--|
| Dialysis | Canadian Institute for Health Information Discharge Abstract Database | International Classification of Diseases 9 th Revision | V451, V560, V568, 99673 |
| | | International Classification of Diseases 10 th Revision | T824, Y602, Y612, Y622, Y841, Z49, Z992 |
| | | Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures | 5127, 5142, 5143, 5195, 6698 |
| | | Canadian Classification of Health Interventions | 1PZ21, 1OT53DATS, 1OT53HATS, 1OT53LATS, 1SY55LAFT, 7SC59QD, 1KY76, 1KG76MZXXA, 1KG76MZXXN, 1JM76NC, 1JM76NCXXN |
| | Ontario Health Insurance Plan | Fee code | R850, G324, G336, G327, G862, G865, G099, R825, R826, R827, R833, R840, R841, R843, R848, R851, R946, R943, R944, R945, R941, R942, Z450, Z451, Z452, G864, R852, R853, R854, R885, G333, H540, H740, R849, G323, G325, G326, G860, G863, G866, G330, G331, G332, G861, G082, G083, G085, G090, G091, G092, G093, G094, G095, G096, G294, G295 |
| Kidney transplant | Canadian Institute for Health Information Discharge Abstract Database | Canadian Classification of Health Interventions | 1PC85 |
| | Ontario Health Insurance Plan | Fee code | S435, S434 |
| Palliative care | Canadian Institute for Health Information Discharge Abstract Database | Patient service | 58 |
| | Ontario Health Insurance Plan | Fee code | C945, C882, C982, W872, W972, B966, B998, B997, G511, W882, W982, K023 (inpatient or LTC use only) |
| Acute kidney injury | Canadian Institute for Health Information Discharge Abstract Database and National Ambulatory Care Reporting System | International Classification of Diseases 10 th Revision | N17 |

Table 6. Diagnostic codes for outcome variables

| Variable | Database | Code Set | Code |
|--|--|----------------|--|
| Mortality | Registered Persons Database | Vital status | Vital status field |
| Hospital-based acute dialysis | Ontario Health Insurance Plan | Fee code | R849, G323, G866, G330, G331, G093, G095, G294, G2955 associated with hospital admission |
| Health care cost | Assistive Device Program, Client Agency Program Enrolment, Continuing Care Reporting System, Canadian Institute for Health Information Discharge Abstract Database and National Ambulatory Care Reporting System, Home Care Database, National Rehabilitation Reporting System, Ontario Drug Benefits, Ontario Health Insurance Plan, Ontario Mental Health Reporting System | | Institute for Clinical Evaluative Sciences costing macro ⁷ |
| Outpatient physician visit by any one of: family physician, general internist, nephrologist, urologist | Ontario Health Insurance Plan | Fee code | GP/FP: A001, A003, A004, A005, A006, A007, A008, A900, A901, A905, A911, A912, A967, K131, K132, K140, K141, K142, K143, K144, W003, W008, W121 Internal Medicine: A135, C135 Nephrology: A135, A161, A163, A164, A165, A166, A168, C101, C138, G860, G323, G333, E083, C132, C135, C137, C139, H540, G325, G326, G860, G865, G866, G330, G331, G332, G861, G864 Urology: A355, A356, A353, A354, C355, C356, C353, C354 Z606, Z628, Z632, Z633, Z634, S655, S654 |
| | Institute for Clinical Evaluative Sciences Physician Database | Main specialty | GP/FP, INTERNAL MEDICINE, NEPHROLOGY, UROLOGY |
| Serum creatinine tests | Dynacare | | 067A |
| | Cerner | | Test done="A" |
| | Ontario Health Insurance Plan | Fee code | L067 |
| Urine protein tests (dipstick, albumin-to-creatinine ratio, protein-to-creatinine ratio) | Dynacare | | 05DR, 05DU, P/CR, P/CM, 208Y, 208Z, 253 |
| | Ontario Health Insurance Plan | Fee code | L253, L254, L255, L633, L634, L641, G009, G010 |

Table 7. Characteristics used to derive propensity scores

| Category | Variable |
|---------------------------------|---|
| Demographics | Age, sex |
| Income | Income quintile |
| Index date | Year of cohort entry |
| Residence status | Location, long-term care status |
| Pharmacy | Forward sortation area |
| Co-morbid conditions | Abdominal aortic aneurysm repair, atrial fibrillation/flutter, major cancer, chronic liver disease, chronic obstructive pulmonary disease, coronary artery disease, dementia, diabetes, heart failure, hypertension, nephrolithiasis, osteoarthritis, Parkinson's disease, peripheral vascular disease, rheumatoid arthritis, stroke/transient ischemic attack |
| Co-morbidity indices | Charlson co-morbidity index, aggregated diagnosis group point score |
| Laboratory characteristics | Baseline serum creatinine ^a , number of days baseline serum creatinine was measured prior to ED index date ^a , proportion with baseline serum creatinine ≤ 0.3 mg/dL, serum creatinine at ED visit (each AKI stage) ^a , albumin-to-creatinine ratio, serum potassium ^a , serum sodium ^a , AKI stage ^b , eGFR category |
| Health care utilization | Prior hospitalizations, prior ED visits, Family physician encounter, Internal Medicine visit, Nephrologist visit, Urologist visit, coronary angiogram or revascularization, computed tomography with contrast, echocardiogram, cardiac stress test, abdominal ultrasound, intervention for kidney stones |
| Medication class ^b | Ontario Drug Benefit eligibility, number of unique drug identification numbers, number of unique drug names angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, antibacterial, anticoagulant, antidepressant (selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor), antineoplastic, antiplatelet, antipsychotic medication, beta-adrenergic antagonist, calcium channel blocker, corticosteroid, xanthine oxidase inhibitor or uricosuric agent, anti-retroviral medication, immunosuppressive medication, lithium, non-potassium sparing diuretic, non-steroidal anti-inflammatory drug ^c , oral hypoglycemic agent or insulin, potassium-sparing diuretic, prostatic hyperplasia medication, proton pump inhibitor, statin |
| ED and hospital Characteristics | Hospital institution ^d , ED registrations in last 12 hours ^a , hospital admissions in last 24 hours ^a , hospital discharges in last 24 hours ^a , proportion of ED registrations admitted to hospital, ED length of stay, time waiting for physician assessment, Canadian Triage Acuity Scale, time of day (weekday and weekend), season of the year, ED physician specialty training. |

Abbreviations: AKI, acute kidney injury; ED, emergency department; eGFR, estimated glomerular filtration rate.

We considered a total of 93 variables to derive propensity scores for the AKI and discharge subpopulations. In the AKI subpopulation (comparing patients discharged home from the ED with AKI versus patients admitted to hospital with AKI), a total 92 variables were used to derive the propensity score. The ED length of stay variable was not included because admitted patients may remain in the ED until an inpatient bed is available, inflating the ED length of stay (defined as time of registration to time patient physically left the ED). In the discharge subpopulation (comparing patients discharged home from the ED with AKI versus patients discharged home from the ED with no AKI), a total of 91 variables were used to derive the propensity score. ED visit serum creatinine and AKI stage were not included in the model. To convert serum creatinine from traditional units (mg/dL) to SI units ($\mu\text{mol/L}$), multiply by 88.42.

^a Continuous variables in the propensity score model.

^b Medications available for Ontario Drug Benefit eligible patients.

^c Excludes acetylsalicylic acid.

^d Thirteen hospital institutions in Southwestern Ontario share the same electronic health record (Cerner, Missouri, USA).

Table 8. Definition and staging of acute kidney injury

| Stage | Serum creatinine |
|-------|---|
| 1 | 1.5-1.9 times pre-ED baseline OR ≥0.3mg/dL absolute increase |
| 2 | 2.0-2.9 times pre-ED baseline |
| 3 | 3.0 times pre-ED baseline OR an increase in serum creatinine to >4 mg/dL OR the initiation of renal replacement therapy |

Abbreviations: AKI, acute kidney injury; ED, emergency department.

To convert serum creatinine from traditional units (mg/dL) to SI units (µmol/L), multiply by 88.42.

Definition and staging of AKI was adapted from the 2012 Kidney Diseases: Improving Global Outcomes clinical practice guidelines.¹ Urine output was not available in our data sources and therefore was not included in our definition of AKI.

Serum creatinine measured 7 to 365 days before the ED visit served as the baseline (pre-ED baseline). Pre-ED baseline serum creatinine measurements were chosen no earlier than seven days before the ED visit to avoid potentially unstable baseline values.

Kidney Diseases: Improving Global Outcomes clinical practice guidelines defined the AKI as a relative increase of 1.5-1.9 times within 7 days from baseline or an absolute increase in serum creatinine of 0.3 mg/dL or more within 48 hours from baseline.

Table9. Additional baseline characteristics of patients discharged home from the emergency department with acute kidney injury

| | Patients discharged from the ED with AKI, n (%) ^a | | | |
|---|--|-----------|----------------------|------------------------|
| | All patients | AKI stage | | |
| | | 1 | 2 | 3 |
| Cohort size | 6346 | 6012 | 290 | 44 |
| Demographics | | | | |
| Neighbourhood income quintile | | | | |
| 1 | 1401 (22) | 1314 (22) | 78 (27) [†] | 9 (21) [§] |
| 2 | 1353 (21) | 1290 (22) | 54 (19) | 9 (21) |
| 3 | 1307 (21) | 1238 (21) | 62 (21) | 7 (16) ^{‡§} |
| 4 | 1046 (17) | 996 (17) | 42 (15) | 8 (18) [§] |
| 5 | 1140 (18) | 1079 (18) | 50 (17) | 11 (25) ^{‡§} |
| Not reported ^b | 99 (2) | | | |
| Pharmacyforward sortation area ^c | 5214 (82) | 4945 (82) | 233 (80) | 36 (82) |
| | | | | |
| Co-morbid conditions^d | | | | |
| Abdominal aortic aneurysm repair | 49 (0.8) | 37 | ≤5 (≤2) | ≤5 (≤11) [‡] |
| Atrial fibrillation or flutter | not reported | 627 (10) | 23 (8) | ≤5 (≤11) [‡] |
| Major cancer ^e | 1056 (17) | 994 (17) | 53 (18) | 9 (21) [‡] |
| Chronic obstructive pulmonary disease | not reported | 369 (6) | 22 (8) | ≤5 (≤11) ^{‡§} |
| Dementia | not reported | 591 (10) | 39 (13) [†] | ≤5 (≤11) ^{‡§} |
| Osteoarthritis | not reported | 431 (7) | 26 (9) | ≤5 (≤11) ^{‡§} |
| Parkinson's disease | not reported | 32 (0.5) | ≤5 (≤2) | ≤5 (≤11) ^{‡§} |
| Peripheral vascular disease | not reported | 178 (3) | ≤5 (≤2) | ≤5 (≤11) |
| Rheumatoid arthritis | not reported | 429 (7) | 22 (8) | ≤5 (≤11) |
| Cerebrovascular disease | not reported | 243 (4) | 14 (5) | ≤5 (≤11) ^{‡§} |
| Charlson co-morbidity index ^f | | | | |
| 0 | 4181 (66) | 3962 (66) | 188 (65) | 31 (71) [§] |
| 1 | not reported | 661 (11) | 33 (11) | ≤5 (≤11) |
| 2 | not reported | 606 (10) | 35 (12) | ≤5 (≤11) ^{‡§} |
| ≥3 | 824 (13) | 783 (13) | 34 (12) | 7 (16) [§] |
| | | | | |
| Medication utilization^g | | | | |
| Ontario Drug Benefiteligible patients | 4605 (73) | 4367 (73) | 213 (74) | 25 (57) |

| | | | | |
|--|---------------|---------------|----------------------|------------------------|
| Patients in long-term care ^h | not reported | 171 (4) | 13 (6) [†] | ≤5 (≤11) [‡] |
| Medication class ⁱ | | | | |
| Anticoagulant | not reported | 689 (16) | 32 (15) | ≤5 (≤11) |
| Antidepressant (selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor) | 774 (17) | 728 (17) | 40 (19) | 6 (24) ^{‡§} |
| Antineoplastic (chemotherapy) | not reported | 108 (2) | ≤5 (≤2) | ≤5 (≤11) ^{‡§} |
| Antiplatelet | not reported | 714 (16) | 31 (15) | ≤5 (≤11) ^{‡§} |
| Beta-adrenergic antagonist | 1781 (39) | 1705 (39) | 66 (31) [†] | 10 (40) [§] |
| Calcium channel blocker | not reported | 1499 (34) | 64 (30) | ≤5 (≤11) ^{‡§} |
| Corticosteroid | 1188 (26) | 1119 (26) | 63 (30) | 6 (24) [§] |
| Xanthine oxidase inhibitor or uricosuric agent | not reported | 302 (7) | ≤5 (≤2) [†] | ≤5 (≤11) ^{‡§} |
| Anti-retroviral medication | not reported | 7 (0.2) | ≤5 (≤2) | ≤5 (≤11) |
| Immunosuppressive medication | not reported | 166 (4) | 13 (6) [†] | ≤5 (≤11) |
| Lithium | not reported | 30 (0.7) | ≤5 (≤2) [†] | ≤5 (≤11) [‡] |
| Oral hypoglycemic agents or insulin | 1403 (31) | 1346 (31) | 52 (24) [†] | 5 (20) ^{‡§} |
| Prostatic hyperplasia medication (alpha-1-adrenoceptor antagonist or 5-alpha reductase inhibitor) | not reported | 279 (6) | 13 (6) | ≤5 (≤11) |
| Proton pump inhibitor | 1651 (36) | 1571 (36) | 68 (32) | 12 (48) ^{‡§} |
| Statin | 2174 (47) | 2072 (47) | 93 (44) | 9 (36) ^{‡§} |
| Number of unique drug names, mean (standard deviation) | 6 (6) | 6 (6) | 6 (6) | 3 (5) ^{‡§} |
| Number of unique drug identification numbers | | | | |
| Mean (standard deviation) | 6 (6) | 6 (6) | 6 (7) | 4 (6) ^{‡§} |
| Median (interquartile range) | 5 (0-10) | 5 (0-10) | 5 (0-10) | 0 (0-7) |
| | | | | |
| Pre-ED baseline kidney function^l | | | | |
| Baseline serum creatinine in mg/dL, median (interquartile range) | 1.0 (0.8-1.3) | 1.0 (0.8-1.3) | 0.8 (0.6-1.0) | 0.8 (0.6-1.0) |
| Days measurement taken prior to ED visit, median (interquartile range) | 106 (44-207) | 106 (44-206) | 126 (45-215) | 115 (46-256) |
| CKD risk category ^k | | | | |
| Low risk | not reported | 678 (11) | 41 (14) | ≤5 (≤11) |
| Moderate risk | not reported | 293 (5) | 15 (5) | ≤5 (≤11) ^{‡§} |
| High risk | not reported | 366 (6) | 16 (6) | ≤5 (≤11) |
| Very high risk | not reported | 654 (11) | 12 (4) [†] | ≤5 (≤11) [§] |
| | | | | |
| ED visit laboratory characteristics | | | | |
| Serum potassium measured | 5854 (92) | 5552 (92) | 264 (91) | 38 (86) |
| Median (interquartile range) | 4.1 (3.8-4.5) | 4.1 (3.8-4.5) | 4.1 (3.6-4.5) | 4.2 (3.6-4.8) |
| Serum sodium measured | 5854 (92) | 5552 (92) | 264 (91) | 38 (86) |

| | | | | |
|---|---------------|---------------|----------------------|------------------------|
| Median (interquartile range) | 138 (135-140) | 138 (135-140) | 137 (134-139) | 134 (131-139) |
| Previous health care utilization^l | | | | |
| Number of ED visits in the previous 30 days | | | | |
| 0 | 5232 (82) | 4950 (82) | 245 (85) | 37 (84) |
| 1 | not reported | 293 (5) | 9 | ≤5 (≤11) |
| 2 | not reported | 229 (4) | 10 | ≤5 (≤11) ^{‡§} |
| ≥3 | not reported | 540 (9) | 26 | ≤5 (≤11) ^{‡§} |
| Number of ED visits in the previous 31 to 365 days | | | | |
| 0 | 3836 (60) | 3628 (60) | 176 (61) | 32 (73) ^{‡§} |
| 1 | not reported | 1126 (19) | 52 (18) | ≤5 (≤11) ^{‡§} |
| 2 | not reported | 572 (10) | 26 | ≤5 (≤11) |
| ≥3 | not reported | 686 (11) | 36 | ≤5 (≤11) ^{‡§} |
| Number of hospitalizations in the previous 30 days | | | | |
| 0 | 5865 (92) | 5561 (93) | 266 (92) | 38 (86) ^{‡§} |
| 1 | not reported | 250 (4) | 13 | ≤5 (≤11) ^{‡§} |
| 2 | not reported | 120 (2) | ≥6 (≥2) | ≤5 (≤11) ^{‡§} |
| ≥3 | not reported | 81 (1) | ≤5 (≤2) | ≤5 (≤11) ^{‡§} |
| Number of hospitalizations in the previous 31 to 365 days | | | | |
| 0 | 4894 (77) | 4646 (77) | 212 (73) | 36 (82) ^{‡§} |
| 1 | not reported | 895 (15) | 53 (18) | ≤5 (≤11) ^{‡§} |
| 2 | not reported | 295 (5) | 14 (5) | ≤5 (≤11) ^{‡§} |
| ≥3 | not reported | 176 (3) | 11 (4) | ≤5 (≤11) |
| Family physician visits | | | | |
| 0 | not reported | 88 (2) | 7 (2) | ≤5 (≤11) ^{‡§} |
| 1-2 | not reported | 339 (6) | 15 (5) | ≤5 (≤11) |
| 3-4 | not reported | 590 (10) | 24 (8) | ≤5 (≤11) |
| 5-6 | 862 (13.6) | 813 (14) | 42 (15) | 7 (16) |
| 7-8 | 735 (11.6) | 689 (12) | 40 (14) | 6 (14) |
| 9-10 | not reported | 659 (11) | 27 (9) | ≤5 (≤11) |
| ≥11 | 2990 (47.1) | 2834 (47) | 135 (47) | 21 (48) ^{‡§} |
| Abdominal ultrasound ^m | 1530 (24.1) | 1456 (24) | 59 (20) | 15 (34) ^{‡§} |
| Echocardiogram | not reported | 1097 (18) | 34 (12) [†] | ≤5 (≤11) ^{‡§} |
| Cardiac stress test | not reported | 931 (16) | 34 (12) [†] | ≤5 (≤11) ^{‡§} |
| Intervention for kidney stones ⁿ | not reported | 73 (1) | ≤5 (≤2) | ≤5 (≤11) |
| | | | | |

| ED and hospital characteristics | | | | |
|---|---------------|---------------|-----------------------|--------------------------|
| Institution^o | | | | |
| 1 | 1754 (286) | 1665 (28) | 78 (26.9) | 11 (25.0) |
| 2 | 1482 (23) | 1400 (23) | 70 (24.1) | 12 (27.3) |
| 3 | not reported | 608 (10) | 36 | ≤5 (≤11.4) ^{‡§} |
| 4 | not reported | 435 (7) | 26 | ≤5 (≤11.4) |
| 5 | not reported | 145 (2) | ≤5 (≤1.7) | ≤5 (≤11.4) [‡] |
| 6 | not reported | 42 (0.7) | ≤5 (≤1.7) | ≤5 (≤11.4) ^{‡§} |
| 7 | not reported | 569 (10) | 35 (12.1) | ≤5 (≤11.4) |
| 8 | not reported | 241 (4) | 7 (2.4) | ≤5 (≤11.4) |
| 9 | not reported | 338 (6) | 10 (3.4) [†] | ≤5 (≤11.4) [§] |
| 10 | not reported | 366 (6) | 10 (3.4) [†] | ≤5 (≤11.4) |
| 11 | not reported | 148 (3) | ≤5 (≤1.7) | ≤5 (≤11.4) ^{‡§} |
| 12 | not reported | 32 (0.5) | ≤5 (≤1.7) | ≤5 (≤11.4) ^{‡§} |
| 13 | not reported | 23 (0.4) | ≤5 (≤1.7) | ≤5 (≤11.4) |
| ED and hospital activity | | | | |
| Standardized number of registrations in the last 12h^p | | | | |
| Mean (standard deviation) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) ^{‡§} |
| Median (interquartile range) | 1.1 (0.9-1.3) | 1.1 (0.9-1.3) | 1.1 (0.9-1.3) | 1.0 (0.8-1.3) |
| Standardized number of hospital admissions in the last 24h^q | | | | |
| Mean (standard deviation) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) [‡] |
| Median (interquartile range) | 1.1 (0.8-1.3) | 1.1 (0.8-1.3) | 1.1 (0.8-1.3) | 1.2 (0.9-1.3) |
| Standardized number of hospital discharges in the last 24^r | | | | |
| Mean (standard deviation) | 1.1 (0.4) | 1.1 (0.3) | 1.1 (0.4) | 1.1 (0.4) ^{‡§} |
| Median (interquartile range) | 1.1 (0.8-1.2) | 1.1 (0.8-1.2) | 1.1 (0.8-1.2) | 1.3 (0.9-1.4) |
| Proportion of ED registrations resulting in hospitalization ^s | 47% | 47% | 49% | 48% |
| ED seasonal and time characteristics | | | | |
| Weekday (Monday-Friday) | | | | |
| 0700 to <1700 | 2463 (53) | 2311 (54) | 125 (60) [†] | 27 (71) ^{‡§} |
| 1700 to <2400 | 1624 (35) | 1553 (35) | 62 (30) [†] | 9 (24) ^{‡§} |
| 0000 to <0700 | not reported | 540 (12) | 23 (11) | ≤5 (≤11) ^{‡§} |
| Weekend (Saturday-Sunday) | | | | |
| 0700 to <1700 | not reported | 817 (51) | 37 (46) | ≤5 (≤11) |
| 1700 to <2400 | not reported | 572 (36) | 29 (36) | ≤5 (≤11) ^{‡§} |
| 0000 to <0700 | not reported | 219 (14) | 14 (18) [†] | ≤5 (≤11) ^{‡§} |
| Season^t | | | | |
| Fall | 1502 (24) | 1418 (24) | 71 (25) | 13 (30) ^{‡§} |
| Winter | 1446 (23) | 1358 (23) | 77 (27) | 11 (25) |

| | | | | |
|--|--------------|-----------|----------------------|-------------------------|
| Spring | 1635 (26) | 1563 (26) | 63 (22) [†] | 9 (21) [‡] |
| Summer | 1763 (28) | 1673 (28) | 79 (27) | 11 (25) |
| ED physician training | | | | |
| Emergency Medicine | 4642 (73) | 4403 (73) | 210 (72) | 29 (66) ^{‡§} |
| Family Medicine | 1338 (21) | 1264 (21) | 62 (21) | ≥10 (≥24) ^{‡§} |
| Other | not reported | 345 (6) | 18 (6) | ≤5 (≤11) |
| ED patient acuity and wait times | | | | |
| 90% percentile ED length of stay, in hours | | | | |
| Canadian Triage Acuity Scale1 and 2 ^u | 9 | 9 | 10 | 7 |
| Canadian Triage Acuity Scale3 | 9 | 9 | 8 | 10 |
| Canadian Triage Acuity Scale4 and 5 | 8 | 8 | 9 | 8 |

Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; ED, emergency department.

A standardized difference of 10% or greater was found between the following two AKI subgroup comparisons: [†] stage 1 versus stage 2; [‡] stage 1 versus stage 3; and [§] stage 2 versus stage 3. To convert serum creatinine from traditional units (mg/dL) to SI units (µmol), multiply by 88.42.

^a Reported as n(%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in the case of five or fewer patients. The total number of patients was not reported if there were other calculations that result in the re-identification of five or fewer patients.

^b Missing income quintile imputed as 3.

^c Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of individuals who live in the same region as the pharmacy that provided them with prescription medications.

^d Look-back window for co-morbidities was five years unless otherwise noted.

^e Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus.

^f Look-back window for Charlson co-morbidity index was two years.

^g Look-back window for medication utilization was 120 days.

^h Patients in long-term care can only be identified from the Ontario Drug Benefits database.

ⁱ Percentages reported are based on the number of Ontario Drug Benefits eligible patients.

^j Pre-ED visit look-back window: 7 to 365 days.

^k Risk categories derived from the 2012 Kidney Diseases: Improving Global Outcomes clinical practice guidelines for CKD. Urine dipstick and urine protein values were converted to an estimate albumin-to-creatinine ratio.²

^l Look-back window for health care utilization was 365 days unless otherwise noted.

^m Not specific for the assessment of the kidneys.

ⁿ Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal.

^o For privacy considerations, numbers of patients by AKI stage were not identified by individual hospital institution.

^p Standardized to the mean number of registrations that occurred in the last 12-hour period over the last 14 days.

^q Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days.

^r Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days.

^s Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution's number of registrations occurring in the last 24 hours.

^t Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20.

^uPatients with a Canadian Triage Acuity Scale of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively. Patients with a Canadian Triage Acuity Scale of 3 or 4 need to be seen within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively. Patients with a Canadian Triage Acuity Scale of 5 need to be seen within 120 minutes 80% of the time.

Table 10. Most common main diagnoses assigned by physicians to patients discharged home from the emergency department with acute kidney injury

| Rank | ED main diagnosis ^a | | Frequency |
|------|--------------------------------|--|-----------|
| | Code ^b | Description | |
| 1 | R07 | Pain in throat and chest | 515 |
| 2 | R10 | Abdominal and pelvic pain | 447 |
| 3 | N23 | Unspecified renal colic | 309 |
| 4 | R55 | Other disorders of urinary system | 248 |
| 5 | N39 | Syncope and collapse | 219 |
| 6 | J18 | Pneumonia, organism unspecified | 175 |
| 7 | R53 | Malaise and fatigue | 159 |
| 8 | E86 | Other non-infective gastroenteritis and colitis | 150 |
| 9 | I50 | Volume depletion | 128 |
| 10 | I48 | Atrial fibrillation and flutter | 123 |
| 11 | R06 | Abnormalities of breathing | 116 |
| 12 | R42 | Dizziness and giddiness | 116 |
| 13 | K52 | Calculus of kidney and ureter | 111 |
| 14 | I20 | Heart failure | 110 |
| 15 | R11 | Nausea and vomiting | 98 |
| 16 | N20 | Angina pectoris | 89 |
| 17 | R00 | Cellulitis | 88 |
| 18 | R33 | Diarrhea and gastroenteritis of presumed infectious origin | 77 |
| 19 | G45 | Other chronic obstructive pulmonary disease | 77 |
| 20 | J44 | Abnormalities of heart beat | 76 |

Abbreviations: ED, emergency department.

^a Assigned by ED physicians after assessment of the patient.

^b Diagnostic codes derived from the International Classification of Diseases 10th Revision.

Table 11. Baseline characteristics of the acute kidney injury subpopulation before and after propensity score matching

| Statistic | Patients with AKI in the ED | | | | | |
|-----------------------------------|-------------------------------------|----------------------|-----------------------------|--|----------------------|-----------------------------|
| | Before matching, n (%) ^a | | Standardized difference (%) | Successfully matched 1:1, n (%) ^a | | Standardized difference (%) |
| | Discharged home | Admitted to hospital | | Discharged home | Admitted to hospital | |
| Cohort size | 6346 | 8117 | | 4379 | 4379 | |
| Demographics | | | | | | |
| Age | | | | | | |
| Mean (standard deviation) | 69 (13) | 73 (13) | 32 | 71 (13) | 71 (13) | 2 |
| Median (interquartile range) | 70 (58-79) | 75 (64-83) | | 73 (62-81) | 74 (62-81) | |
| 40 to <50 | 683 (11) | 445 (6) | 19 | 305 (7) | 307 (7) | 0 |
| 50 to <65 | 1643 (26) | 1610 (20) | 15 | 962 (22) | 991 (23) | 1 |
| 65 to <70 | 731 (12) | 812 (10) | 5 | 509 (12) | 439 (10) | 5 |
| 70 to <75 | 827 (13) | 1026 (13) | 1 | 615 (14) | 548 (13) | 4 |
| 75 to <80 | 917 (15) | 1340 (17) | 6 | 695 (16) | 694 (16) | 0 |
| 80 to <85 | 809 (13) | 1390 (17) | 12 | 656 (15) | 717 (16) | 4 |
| 85 to <90 | 514 (8) | 979 (12) | 13 | 439 (10) | 439 (10) | 0 |
| ≥90 | 222 (4) | 515 (6) | 13 | 198 (5) | 244 (6) | 5 |
| Sex, female | 2948 (47) | 3737 (46) | 1 | 2037 (47) | 2037 (47) | 0 |
| Year of cohort entry (index date) | | | | | | |
| 2003 | 344 (5) | 434 (5) | 0 | 242 (6) | 250 (6) | 1 |
| 2004 | 481 (8) | 673 (8) | 3 | 371 (9) | 362 (8) | 1 |
| 2005 | 768 (12) | 892 (11) | 3 | 501 (12) | 505 (12) | 0 |
| 2006 | 842 (13) | 1005 (12) | 3 | 555 (13) | 597 (14) | 3 |
| 2007 | 1059 (17) | 1082 (13) | 10 | 673 (15) | 667 (15) | 1 |
| 2008 | 1002 (16) | 1102 (13) | 6 | 653 (15) | 647 (15) | 0 |
| 2009 | 657 (10) | 964 (12) | 5 | 474 (11) | 471 (11) | 0 |
| 2010 | 620 (10) | 1052 (13) | 10 | 471 (11) | 472 (11) | 0 |
| 2011 | 573 (9) | 913 (11) | 7 | 439 (10) | 408 (9) | 2 |
| Rural residence | 969 (15) | 1302 (16) | 2 | 685 (16) | 652 (15) | 2 |
| Neighbourhood income quintile | | | | | | |
| 1 | 1401 (22) | 1892 (23) | 3 | 971 (22) | 989 (23) | 1 |
| 2 | 1353 (21) | 1748 (21) | 1 | 942 (22) | 932 (21) | 0 |
| 3 | 1307 (21) | 1608 (20) | 2 | 978 (22) | 957 (22) | 1 |

| | | | | | | |
|---|--------------|-----------|----|-----------|-----------|---|
| 4 | 1046 (17) | 1342 (17) | 0 | 731 (17) | 732 (17) | 0 |
| 5 | 1140 (18) | 1391 (17) | 2 | 757 (17) | 769 (18) | 1 |
| Pharmacy forward sortation area ^b | 5214 (82) | 6513 (80) | 5 | 3562 (81) | 3573 (82) | 1 |
| | | | | | | |
| Co-morbid conditions^c | | | | | | |
| Abdominal aortic aneurysm repair | 49 (0.8) | 78 (1) | 2 | 38 (0.9) | 38 (0.9) | 0 |
| Atrial fibrillation or flutter | not reported | 1133 (14) | 11 | 539 (12) | 547 (13) | 1 |
| Chronic liver disease | not reported | 722 (9) | 8 | 327 (8) | 325 (7) | 0 |
| Chronic obstructive pulmonary disease | not reported | 907 (11) | 18 | 352 (8) | 364 (8) | 1 |
| Coronary artery disease ^d | 2160 (34) | 3124 (39) | 9 | 1614 (37) | 1636 (37) | 1 |
| Dementia | not reported | 1204 (15) | 15 | 531 (12) | 540 (12) | 1 |
| Diabetes | 2405 (38) | 3496 (43) | 11 | 1728 (40) | 1703 (39) | 1 |
| Heart failure | not reported | 2591 (32) | 23 | 1168 (27) | 1170 (27) | 0 |
| Hypertension | 4783 (75) | 6454 (80) | 10 | 3475 (79) | 3475 (79) | 0 |
| Major cancer ^e | 1056 (17) | 1735 (21) | 12 | 829 (19) | 843 (19) | 1 |
| Nephrolithiasis | not reported | 191 (2) | 2 | 117 (3) | 110 (3) | 1 |
| Osteoarthritis | not reported | 631 (8) | 2 | 344 (8) | 330 (8) | 2 |
| Parkinson's disease | not reported | 82 (1) | 6 | 32 (0.7) | 32 (0.7) | 0 |
| Peripheral vascular disease | not reported | 371 (5) | 9 | 154 (4) | 156 (4) | 1 |
| Rheumatoid arthritis | not reported | 604 (7) | 1 | 317 (7) | 309 (7) | 0 |
| Cerebrovascular disease | not reported | 396 (5) | 4 | 221 (5) | 208 (5) | 1 |
| Charlson co-morbidity index ^f | | | | | | |
| 0 | 4181 (66) | 4338 (53) | 26 | 2676 (61) | 2574 (59) | 5 |
| 1 | not reported | 1017 (13) | 5 | 515 (12) | 541 (12) | 2 |
| 2 | not reported | 1110 (14) | 11 | 489 (11) | 575 (13) | 6 |
| ≥3 | 824 (13) | 1652 (20) | 20 | 699 (16) | 689 (16) | 1 |
| Aggregated Diagnosis Groupspoint score ^g | | | | | | |
| 0-2 | not reported | 375 (5) | 3 | 194 (4) | 219 (5) | 3 |
| 3-5 | 1417 (22) | 1517 (19) | 9 | 927 (21) | 891 (20) | 2 |
| ≥6 | 4589 (72) | 6225 (77) | 10 | 3255 (74) | 3265 (75) | 1 |
| | | | | | | |
| Medication utilization^h | | | | | | |
| Ontario Drug Benefitelegible patients | 4605 (73) | 6748 (83) | 26 | 3459 (79) | 3477 (79) | 1 |
| Patients in long-term care ⁱ | not reported | 458 (6) | 13 | 172 (4) | 188 (4) | 2 |

| | | | | | | |
|--|--------------|-----------|----|-----------|-----------|---|
| Medication class ¹ | | | | | | |
| Angiotensin-converting enzyme inhibitor or angiotensin receptor II blocker | 2750 (60) | 4026 (60) | 0 | 2065 (60) | 2074 (60) | 0 |
| Antibiotic | 2041 (44) | 3214 (48) | 7 | 1567 (45) | 1569 (45) | 0 |
| Anticoagulant | not reported | 1253 (19) | 8 | 594 (17) | 609 (18) | 1 |
| Antidepressant (selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor) | 774 (17) | 1151 (17) | 1 | 566 (16) | 563 (16) | 0 |
| Antineoplastic (chemotherapy) | not reported | 150 (2) | 2 | 83 (2) | 82 (2) | 0 |
| Antiplatelet | not reported | 1028 (15) | 3 | 557 (16) | 558 (16) | 0 |
| Antipsychotic medication | not reported | 497 (7) | 3 | 226 (7) | 228 (7) | 0 |
| Beta-adrenergic antagonist | 1781 (39) | 2712 (40) | 3 | 1385 (40) | 1381 (40) | 1 |
| Calcium channel blocker | not reported | 2357 (35) | 2 | 1193 (35) | 1196 (34) | 0 |
| Corticosteroid | 1188 (26) | 1904 (28) | 5 | 935 (27) | 943 (27) | 0 |
| Xanthine oxidase inhibitor or uricosuric agent | not reported | 576 (9) | 7 | 245 (7) | 262 (8) | 2 |
| Anti-retroviral medication | not reported | 12 (0.2) | 0 | 6 (0.2) | ≤5 (≤0.1) | 6 |
| Immunosuppressive medication | not reported | 291 (4) | 2 | 144 (4) | 127 (4) | 3 |
| Lithium | not reported | 45 (0.7) | 0 | 23 (0.7) | 21 (0.6) | 1 |
| Non-potassium sparing diuretic | 2609 (57) | 4213 (62) | 12 | 2034 (59) | 2071 (60) | 2 |
| Non-steroidal anti-inflammatory drug | 892 (19) | 1245 (18) | 3 | 660 (19) | 657 (19) | 0 |
| Oral hypoglycemic agent or insulin | 1403 (31) | 2069 (31) | 0 | 1039 (30) | 1016 (29) | 2 |
| Potassium-sparing diuretic | not reported | 1013 (15) | 9 | 445 (13) | 481 (14) | 3 |
| Prostatic hyperplasia medication | not reported | 439 (7) | 0 | 217 (6) | 211 (6) | 1 |
| Proton pump inhibitor | 1651 (36) | 2563 (38) | 4 | 1260 (36) | 1289 (37) | 1 |
| Statin | 2174 (47) | 2932 (43) | 8 | 1584 (46) | 1563 (45) | 2 |
| Number of unique drug identification numbers | | | | | | |
| Mean (standard deviation) | 6 (6) | 8 (7) | 27 | 7 (6) | 7 (6) | 2 |
| Median (interquartile range) | 5(0-10) | 7 (0-11) | | 6 (0-11) | 6 (0-11) | |
| Number of unique drug names | | | | | | |
| Mean (standard deviation) | 6 (6) | 7 (6) | 27 | 6 (6) | 6 (6) | 1 |
| Median (interquartile range) | 5 (0-10) | 6 (0-10) | | 6 (0-10) | 6 (0-10) | |
| | | | | | | |
| Pre-ED baseline kidney function¹ | | | | | | |
| Baseline serum creatinine in mg/dL | | | | | | |

| | | | | | | |
|---|---------------|---------------|----|---------------|---------------|----|
| Mean (standard deviation) | 1.1 (0.6) | 1.3 (0.8) | 23 | 1.2 (0.6) | 1.2 (0.7) | 2 |
| Median (interquartile range) | 1.0 (0.8-1.3) | 1.1 (0.9-1.5) | | 1.0 (0.8-1.3) | 1.0 (0.8-1.4) | |
| Days serum creatinine measurement taken prior to ED visit | | | | | | |
| Mean (standard deviation) | 133 (102) | 121 (99) | 12 | 127 (101) | 128 (101) | 1 |
| Median (interquartile range) | 106 (44-207) | 90 (38-188) | | 98 (41-197) | 100 (40-203) | |
| Proportion with pre-ED serum creatinine ≤0.3mg/dL | not reported | 277 (3) | 4 | 164 (4) | 165 (4) | 1 |
| Baseline eGFR in ml/min/1.73m ² | | | | | | |
| ≥60 | 3919 (61.8) | 3907 (48) | 28 | 2435 (56) | 2386 (55) | 2 |
| 45 to <60 | not reported | 1610 (20) | 8 | 815 (19) | 834 (19) | 1 |
| 30 to <45 | not reported | 1470 (18) | 13 | 695 (16) | 685 (16) | 1 |
| 15 to <30 | not reported | 924 (11) | 16 | 362 (8) | 396 (9) | 2 |
| <15, but not on dialysis | not reported | 206 (3) | 9 | 72 (2) | 78 (2) | 2 |
| Albumin-to-creatinine ratio in mg/g | | | | | | |
| <30 | not reported | 1014 (13) | 10 | 633 (15) | 567 (13) | 5 |
| 30 to <300 | not reported | 363 (5) | 1 | 186 (4) | 208 (5) | 2 |
| ≥300 | not reported | 417 (5) | 5 | 259 (6) | 244 (6) | 1 |
| No measurement | 4657 (73.4) | 6323 (78) | 11 | 3301 (75) | 3360 (77) | 3 |
| CKD risk category ^m | | | | | | |
| Low risk | not reported | 558 (7) | 16 | 422 (10) | 352 (8) | 6 |
| Moderate risk | not reported | 382 (5) | 1 | 201 (5) | 208 (5) | 0 |
| High risk | not reported | 394 (5) | 5 | 248 (6) | 236 (5) | 1 |
| Very high risk | not reported | 1358 (17) | 18 | 551 (13) | 586 (13) | 2 |
| | | | | | | |
| ED visit laboratory characteristics | | | | | | |
| Serum creatinine in mg/dL | | | | | | |
| Mean (standard deviation) | 1.7 (0.8) | 2.4 (1.8) | 54 | 1.8 (0.8) | 1.8 (0.8) | 3 |
| Median (interquartile range) | 1.5 (1.2-1.8) | 1.8 (1.4-2.6) | | 1.5 (1.3-2.0) | 1.6 (1.3-2.0) | |
| Serum potassium in mEq/L | | | | | | |
| Mean (standard deviation) | 4.2 (0.6) | 4.4 (0.9) | 32 | 4.2 (0.6) | 4.3 (0.8) | 7 |
| Median (interquartile range) | 4.1 (3.8-4.5) | 4.3 (3.8-4.9) | | 4.1 (3.8-4.5) | 4.1 (3.7-4.7) | |
| Serum sodium in mEq/L | | | | | | |
| Mean (standard deviation) | 137 (5) | 136 (7) | 25 | 137 (5) | 136 (6) | 22 |
| Median (interquartile range) | 138 (135-140) | 136 (133-139) | | 138 (135-140) | 137 (134-139) | |
| AKI severity | | | | | | |
| Stage 1 | 6012 (95) | 6407 (79) | 48 | 4091 (93) | 4091 (93) | 0 |

| | | | | | | |
|---|--------------|-----------|----|-----------|-----------|---|
| Stage 2 | 290 (5) | 1007 (12) | 28 | 244 (6) | 244 (6) | 0 |
| Stage 3 | 44 (0.7) | 703 (9) | 39 | 44 (1) | 44 (1) | 0 |
| Previous health care utilizationⁿ | | | | | | |
| Number of ED visits in the previous 30 days | | | | | | |
| 0 | 5232 (82) | 6479 (80) | 7 | 3561 (81) | 3539 (81) | 1 |
| 1 | not reported | 451 (6) | 3 | 218 (5) | 242 (6) | 2 |
| 2 | not reported | 373 (5) | 4 | 187 (4) | 180 (4) | 1 |
| ≥3 | not reported | 814 (10) | 4 | 413 (9) | 418 (10) | 0 |
| Number of ED visits in the previous 31 to 365 days | | | | | | |
| 0 | 3836 (60) | 4865 (60) | 1 | 2635 (60) | 2636 (60) | 0 |
| 1 | not reported | 1543 (19) | 1 | 809 (19) | 834 (19) | 1 |
| 2 | not reported | 785 (10) | 1 | 444 (10) | 407 (9) | 3 |
| ≥3 | not reported | 924 (11) | 0 | 491 (11) | 502 (12) | 1 |
| Number of hospitalizations in the previous 30 days | | | | | | |
| 0 | 5865 (92) | 6987 (86) | 21 | 3960 (90) | 3925 (90) | 3 |
| 1 | not reported | 534 (7) | 11 | 222 (5) | 269 (6) | 4 |
| 2 | not reported | 341 (4) | 13 | 113 (3) | 119 (2) | 1 |
| ≥3 | not reported | 255 (3) | 12 | 84 (2) | 66 (2) | 3 |
| Number of hospitalizations in the previous 31 to 365 days | | | | | | |
| 0 | 4894 (77) | 5730 (71) | 15 | 3277 (75) | 3134 (72) | 7 |
| 1 | not reported | 1472 (18) | 8 | 705 (16) | 804 (19) | 6 |
| 2 | not reported | 581 (7) | 10 | 246 (6) | 296 (7) | 5 |
| ≥3 | not reported | 334 (4) | 6 | 151 (3) | 145 (3) | 1 |
| Family physician visits | | | | | | |
| 0 | not reported | 152 (2) | 3 | 60 (1) | 85 (2) | 4 |
| 1-2 | not reported | 393 (5) | 4 | 212 (5) | 241 (6) | 3 |
| 3-4 | not reported | 694 (9) | 4 | 374 (9) | 406 (9) | 3 |
| 5-6 | 862 (14) | 852 (11) | 10 | 558 (13) | 487 (11) | 5 |
| 7-8 | 735 (12) | 915 (11) | 1 | 483 (11) | 498 (11) | 1 |
| 9-10 | not reported | 804 (10) | 3 | 480 (11) | 444 (10) | 3 |
| ≥11 | 2990 (47) | 4307 (53) | 12 | 2212 (51) | 2218 (51) | 0 |

| | | | | | | |
|---|--------------|-----------|----|-----------|-----------|---|
| General internist visits | | | | | | |
| 0 | 4876 (77) | 5631 (69) | 17 | 3236 (74) | 3208 (73) | 1 |
| 1 | 1148 (18) | 1837 (23) | 11 | 863 (20) | 920 (21) | 3 |
| 2 | 252 (4) | 509 (6) | 10 | 219 (5) | 206 (5) | 1 |
| ≥3 | 70 (1) | 140 (2) | 5 | 61 (1) | 45 (1) | 4 |
| Nephrology visits | | | | | | |
| 0 | 6060 (96) | 7621 (94) | 7 | 4153 (95) | 4175 (95) | 2 |
| 1 | 183 (3) | 253 (3) | 1 | 137 (3) | 108 (3) | 4 |
| 2 | 32 (0.5) | 52 (0.6) | 2 | 26 (0.6) | 18 (0.4) | 3 |
| ≥3 | 71 (1) | 191 (2) | 9 | 63 (1) | 78 (2) | 3 |
| Urology visits | | | | | | |
| 0 | 5214 (82) | 6727 (83) | 2 | 3588 (82) | 3650 (83) | 4 |
| 1 | 361 (6) | 437 (5) | 1 | 245 (6) | 227 (5) | 2 |
| 2 | 305 (5) | 334 (4) | 3 | 206 (5) | 169 (4) | 4 |
| ≥3 | 466 (7) | 619 (8) | 1 | 340 (8) | 333 (8) | 1 |
| Imaging and investigations | | | | | | |
| Abdominal ultrasound ^o | 1530 (24) | 2210 (27) | 7 | 883 (20) | 886 (20) | 0 |
| Cardiac stress test | not reported | 1056 (13) | 7 | 50 (1) | 50 (1) | 0 |
| Computed tomography with contrast | not reported | 407 (5) | 11 | 157 (4) | 158 (4) | 0 |
| Coronary angiogram or revascularization | not reported | 157 (2) | 3 | 1080 (25) | 1083 (25) | 0 |
| Echocardiogram | not reported | 1820 (22) | 11 | 91 (2) | 102 (2) | 1 |
| Intervention for kidney stones ^p | not reported | 96 (1) | 0 | 619 (14) | 627 (14) | 1 |
| ED and hospital characteristics | | | | | | |
| Institution^q | | | | | | |
| 1 | 1754 (28) | 2565 (32) | 9 | 1336 (31) | 1317 (30) | 1 |
| 2 | 1482 (23) | 2051 (25) | 4 | 1060 (24) | 1089 (25) | 2 |
| 3 | not reported | 806 (10) | 1 | 464 (11) | 472 (11) | 1 |
| 4 | not reported | 74 (0.9) | 33 | 61 (1) | 62 (1) | 0 |
| 5 | not reported | 150 (2) | 5 | 94 (2) | 107 (2) | 2 |
| 6 | not reported | 70 (0.9) | 2 | 36 (0.8) | 31 (0.7) | 1 |
| 7 | not reported | 833 (10) | 2 | 466 (11) | 447 (10) | 1 |
| 8 | not reported | 332 (4) | 1 | 180 (4) | 186 (4) | 1 |
| 9 | not reported | 369 (5) | 5 | 246 (6) | 242 (6) | 0 |

| | | | | | | |
|--|---------------|---------------|----|---------------|---------------|---|
| 10 | not reported | 657 (8) | 8 | 308 (7) | 295 (7) | 1 |
| 11 | not reported | 139 (2) | 5 | 88 (2) | 90 (2) | 0 |
| 12 | not reported | 39 (0.5) | 1 | 22 (0.5) | 23 (0.5) | 0 |
| 13 | not reported | 32 (0.4) | 0 | 18 (0.4) | 18 (0.4) | 0 |
| ED and hospital activity | | | | | | |
| Standardized number of registrations in the last 12h ^r | | | | | | |
| Mean (standard deviation) | 1.1 (0.3) | 1.1 (0.3) | 14 | 1.1 (0.3) | 1.1 (0.3) | 0 |
| Median (interquartile range) | 1.1 (0.9-1.3) | 1.1 (0.7-1.3) | | 1.1 (0.9-1.3) | 1.1 (0.9-1.3) | |
| Standardized number of hospital admissions in the last 24h ^s | | | | | | |
| Mean (standard deviation) | 1.1 (0.3) | 1.1 (0.3) | 3 | 1.1 (0.3) | 1.1 (0.3) | 0 |
| Median (interquartile range) | 1.1 (0.8-1.3) | 1.1 (0.8-1.3) | | 1.1 (0.8-1.3) | 1.1 (0.8-1.3) | |
| Standardized number of hospital inpatient discharges in the last 24 ^t | | | | | | |
| Mean (standard deviation) | 1.1 (0.4) | 1.1 (0.4) | 3 | 1.1 (0.3) | 1.1 (0.4) | 3 |
| Median (interquartile range) | 1.1 (0.8-1.2) | 1.1 (0.8-1.3) | | 1.1 (0.8-1.3) | 1.1 (0.8-1.3) | |
| Proportion of ED registrations resulting in hospitalization ^u | 47% | 51% | 8 | 50% | 49% | 0 |
| ED seasonal and time characteristics | | | | | | |
| Weekday (Monday-Friday) | | | | | | |
| 0700 to <1700 | 2463 (53) | 3412 (57) | 9 | 1709 (54) | 1779 (56) | 5 |
| 1700 to <2400 | 1624 (35) | 1783 (30) | 11 | 1092 (34) | 999 (31) | 6 |
| 0000 to <0700 | not reported | 750 (13) | 2 | 394 (12) | 404 (13) | 1 |
| Weekend (Saturday-Sunday) | | | | | | |
| 0700 to <1700 | not reported | 1126 (52) | 2 | 589 (50) | 602 (50) | 1 |
| 1700 to <2400 | not reported | 712 (33) | 6 | 405 (34) | 424 (35) | 3 |
| 0000 to <0700 | not reported | 334 (15) | 4 | 190 (16) | 171 (14) | 5 |
| Season ^v | | | | | | |
| Fall | 1502 (24) | 2141 (26) | 6 | 1067 (24) | 1105 (25) | 2 |
| Winter | 1446 (23) | 1925 (24) | 2 | 1033 (24) | 1013 (23) | 1 |
| Spring | 1635 (26) | 1959 (24) | 4 | 1108 (25) | 1086 (25) | 1 |
| Summer | 1763 (28) | 2092 (26) | 5 | 1171 (27) | 1175 (27) | 0 |
| ED physician training | | | | | | |
| Emergency Medicine | 4642 (73) | 5781 (71) | 4 | 3140 (73) | 3152 (72) | 1 |

| | | | | | | |
|---|--------------|------------|----|-----------|-----------|---|
| Family Medicine | 1338 (21) | 1602 (20) | 4 | 945 (22) | 936 (21) | 1 |
| Other | not reported | 734 (9) | 12 | 294 (7) | 291 (7) | 0 |
| ED patient acuity and wait times | | | | | | |
| Canadian Triage Acuity Scale ^w | | | | | | |
| 1 and 2 | 1321 (21) | 3142 (39) | 40 | 1192 (27) | 1185 (27) | 0 |
| 3 | 3797 (60) | 4257 (52) | 15 | 2620 (60) | 2626 (60) | 0 |
| 4 and 5 | 1228 (19) | 718 (9) | 31 | 567 (13) | 568 (13) | 0 |
| Time (in hours) waiting for physician assessment, mean (standard deviation) | | | | | | |
| Canadian Triage Acuity Scale ¹ and 2 | 0.6 (0.8) | 0.46 (0.8) | 16 | 0.6 (0.8) | 0.5 (0.6) | 7 |
| Canadian Triage Acuity Scale ³ | 1.3 (1.3) | 1.2 (1.2) | 12 | 1.3 (1.1) | 1.2 (1.2) | 3 |
| Canadian Triage Acuity Scale ⁴ and 5 | 1.6 (1.4) | 1.7 (1.7) | 2 | 1.4 (1.3) | 1.6 (1.6) | 9 |

Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; ED, emergency department; eGFR, estimated glomerular filtration rate.

To convert serum creatinine from traditional units (mg/dL) to SI units (µmol/L), multiply by 88.42.

^aReported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients.

^bPharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of individuals who live in the same region as the pharmacy that provided them with prescription medications.

^cLook-back window for co-morbidities was five years unless otherwise noted.

^dDoes not include angina.

^eMajor cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus.

^fLook-back window for Charlson co-morbidity Index was two years.

^gThe Aggregated Diagnosis Groupscore, derived from the John Hopkins Adjusted Clinical Groups system, score is a weighted measure of health care utilization as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care involvement. The higher Aggregated Diagnosis Groups score, the greater the co-morbidity. Individuals with an Aggregated Diagnosis Groups score of 0 to 2 reflect low health care costs with no prior hospitalizations; 3 to 5, high health care costs but no prior hospitalizations; 6 or more, high health care costs and at least one prior hospitalization.

^hLook-back window for medication utilization was 120 days.

ⁱPatients in long-term care can only be identified from the Ontario Drug Benefits database.

^jPercentages reported are based on the number of Ontario Drug Benefitseligible patients.

^kDoes not include acetylsalicylic acid.

^lPre-ED visit look-back window: 7 to 365 days.

^mRisk categories derived from the 2012Kidney Diseases: Improving Global Outcomes clinical practice guidelines for CKD. Urine dipstick and urine protein values were converted to an estimate albumin-to-creatinine ratio.²

ⁿLook-back window for health care utilization was 365 days unless otherwise noted.

- ^o Not specific for the assessment of kidneys.
- ^p Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal.
- ^q For privacy considerations, numbers of patients with AKI by ED disposition were not identified by individual hospital institution.
- ^r Standardized to the mean number of registrations that occurred in the last 12-hour period over the last 14 days.
- ^s Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days.
- ^t Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days.
- ^u Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution's number of registrations occurring in the last 24 hours.
- ^v Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20.
- ^w Patients with a Canadian Triage Acuity Scale of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively.
Patients with a Canadian Triage Acuity Scale of 3 or 4 need to be seen within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively.
Patients with a Canadian Triage Acuity Scale of 5 need to be seen within 120 minutes 80% of the time.

Table 12. Baseline characteristics of the discharge subpopulation before and after propensity score matching

| Statistic | Patients discharged home from the ED | | | | | |
|-----------------------------------|--------------------------------------|------------|-------------------------|--|------------|-------------------------|
| | Before matching, n (%) ^a | | Standardized difference | Successfully matched 1:1, n (%) ^a | | Standardized difference |
| | AKI | No AKI | | AKI | No AKI | |
| Cohort size | 6346 | 43422 | | 6188 | 6188 | |
| Demographics | | | | | | |
| Age | | | | | | |
| Mean (standard deviation) | 69 (13) | 63 (14) | 42 | 68 (13) | 69 (14) | 2 |
| Median (interquartile range) | 70 (58-79) | 62 (51-74) | | 70 (58-79) | 71 (58-80) | |
| 40 to <50 | 683 (11) | 9017 (21) | 28 | 676 (11) | 737 (12) | 3 |
| 50 to <65 | 1643 (26) | 15019 (35) | 19 | 1633 (26) | 1453 (24) | 7 |
| 65 to <70 | 731 (12) | 4565 (11) | 3 | 715 (12) | 745 (12) | 1 |
| 70 to <75 | 827 (13) | 4294 (10) | 10 | 804 (13) | 794 (13) | 1 |
| 75 to <80 | 917 (15) | 4202 (10) | 15 | 882 (14) | 890 (14) | 0 |
| 80 to <85 | 809 (13) | 3633 (8) | 14 | 776 (13) | 854 (14) | 4 |
| 85 to <90 | 514 (8) | 1928 (4) | 15 | 498 (8) | 487 (8) | 0 |
| ≥90 | 222 (4) | 764 (2) | 11 | 204 (3) | 228 (4) | 2 |
| Sex, female | 2948 (47) | 24532 (57) | 20 | 2900 (47) | 2940 (48) | 1 |
| Year of cohort entry (index date) | | | | | | |
| 2003 | 344 (5) | 1722 (4) | 7 | 334 (5) | 343 (6) | 0 |
| 2004 | 481 (8) | 2886 (7) | 4 | 474 (8) | 442 (7) | 2 |
| 2005 | 768 (12) | 4003 (9) | 9 | 751 (12) | 773 (13) | 1 |
| 2006 | 842 (13) | 5217 (12) | 4 | 819 (13) | 841 (14) | 1 |
| 2007 | 1059 (17) | 5947 (14) | 8 | 1022 (17) | 996 (16) | 1 |
| 2008 | 1002 (16) | 5892 (14) | 6 | 970 (16) | 1002 (16) | 1 |
| 2009 | 657 (10) | 6226 (14) | 12 | 651 (11) | 615 (10) | 2 |
| 2010 | 620 (10) | 5902 (14) | 12 | 609 (10) | 606 (10) | 0 |
| 2011 | 573 (9) | 5627 (13) | 13 | 558 (9) | 570 (9) | 1 |
| Rural residence | 969 (15) | 6299 (15) | 2 | 940 (15) | 957 (16) | 1 |
| Neighbourhood income quintile | | | | | | |
| 1 | 1401 (22) | 8814 (20) | 4 | 1372 (22) | 1416 (23) | 2 |
| 2 | 1353 (21) | 9012 (21) | 1 | 1306 (21) | 1323 (21) | 1 |

| | | | | | | |
|--|--------------|------------|----|-----------|-----------|---|
| 3 | 1307 (21) | 8757 (20) | 1 | 1372 (22) | 1330 (22) | 2 |
| 4 | 1046 (17) | 7896 (18) | 5 | 1023 (17) | 999 (16) | 1 |
| 5 | 1140 (18) | 8520 (20) | 4 | 1115 (18) | 1120 (18) | 0 |
| Pharmacy forward sortation area ^b | 5214 (82) | 34871 (80) | 5 | 5089 (82) | 5059 (82) | 1 |
| Co-morbid conditions^c | | | | | | |
| Abdominal aortic aneurysm repair | 49 (0.8) | 162 (0.4) | 5 | 47 (0.8) | 55 (0.9) | 0 |
| Atrial fibrillation or flutter | not reported | 1759 (4) | 24 | 606 (10) | 581 (9) | 1 |
| Chronic liver disease | not reported | 2203 (5) | 7 | 412 (7) | 392 (6) | 2 |
| Chronic obstructive pulmonary disease | not reported | 1140 (3) | 18 | 359 (6) | 337 (5) | 2 |
| Coronary artery disease ^d | 2160 (34) | 8678 (20) | 32 | 2062 (33) | 2049 (33) | 0 |
| Dementia | not reported | 2428 (6) | 17 | 607 (10) | 614 (10) | 0 |
| Diabetes | 2405 (38) | 10678 (25) | 29 | 2294 (37) | 2308 (37) | 0 |
| Heart failure | not reported | 3460 (8) | 39 | 1280 (21) | 1226 (20) | 2 |
| Hypertension | 4783 (75) | 25725 (59) | 35 | 4630 (75) | 4668 (75) | 1 |
| Major cancer ^e | 1056 (17) | 5918 (14) | 8 | 1026 (17) | 1016 (16) | 1 |
| Nephrolithiasis | not reported | 666 (2) | 8 | 169 (3) | 170 (3) | 0 |
| Osteoarthritis | not reported | 2580 (6) | 5 | 444 (7) | 434 (7) | 1 |
| Parkinson's disease | not reported | 114 (0.3) | 3 | 32 (0.5) | 38 (0.6) | 1 |
| Peripheral vascular disease | not reported | 1759 (4) | 24 | 174 (3) | 163 (3) | 1 |
| Rheumatoid arthritis | not reported | 2595 (6) | 5 | 445 (7) | 437 (7) | 0 |
| Cerebrovascular disease | not reported | 706 (2) | 15 | 234 (4) | 230 (4) | 1 |
| Charlson co-morbidity index^f | | | | | | |
| 0 | 4181 (66) | 35911 (83) | 39 | 4139 (67) | 4246 (69) | 4 |
| 1 | not reported | 2900 (7) | 15 | 683 (11) | 640 (10) | 2 |
| 2 | not reported | 2657 (6) | 15 | 618 (10) | 639 (10) | 1 |
| ≥3 | 824 (13) | 1954 (5) | 30 | 748 (12) | 663 (11) | 4 |
| Aggregated Diagnosis Groups point score^g | | | | | | |
| 0-2 | not reported | 3704 (9) | 13 | 331 (5) | 292 (5) | 3 |
| 3-5 | 1417 (22) | 13882 (32) | 22 | 1402 (23) | 1479 (24) | 3 |
| ≥6 | 4589 (72) | 25836 (60) | 27 | 4450 (72) | 4411 (71) | 1 |
| Medication utilization^h | | | | | | |
| Ontario Drug Benefit eligible patients | 4605 (73) | 22849 (53) | 42 | 4453 (72) | 4535 (73) | 3 |

| | | | | | | |
|--|--------------|------------|----|-----------|-----------|---|
| Patients in long-term care ¹ | not reported | 441 (1) | 14 | 169 (3) | 159 (3) | 1 |
| Medication class ¹ | | | | | | |
| Angiotensin-converting enzyme inhibitor or angiotensin receptor II blocker | 2750 (60) | 10530 (46) | 28 | 2644 (59) | 2680 (59) | 1 |
| Antibiotic | 2041 (44) | 8297 (36) | 16 | 1954 (44) | 1972 (44) | 1 |
| Anticoagulant | not reported | 2287 (10) | 17 | 673 (15) | 646 (14) | 2 |
| Antidepressant (selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor) | 774 (17) | 3534 (16) | 4 | 738 (17) | 767 (17) | 1 |
| Antineoplastic (chemotherapy) | not reported | 171 (0.7) | 0 | 110 (3) | 121 (3) | 1 |
| Antiplatelet | not reported | 2442 (11) | 16 | 705 (16) | 712 (16) | 0 |
| Antipsychotic medication | not reported | 1335 (6) | 3 | 286 (6) | 298 (6.6) | 1 |
| Beta-adrenergic antagonist | 1781 (39) | 6467 (28) | 22 | 1697 (38) | 1716 (38) | 1 |
| Calcium channel blocker | not reported | 5647 (25) | 21 | 1488 (33) | 1468 (32) | 2 |
| Corticosteroid | 1188 (26) | 5280 (23) | 6 | 1155 (26) | 1172 (26) | 0 |
| Xanthine oxidase inhibitor or uricosuric agent | not reported | 703 (3) | 16 | 273 (6) | 269 (6) | 1 |
| Anti-retroviral medication | not reported | 40 (0.2) | 0 | 7 (0.2) | 8 (0.2) | 0 |
| Immunosuppressive medication | not reported | 784 (3) | 3 | 175 (4) | 184 (4) | 1 |
| Lithium | not reported | 171 (0.7) | 0 | 30 (0.7) | 30 (0.7) | 0 |
| Non-potassium sparing diuretic | 2609 (57) | 8421 (37) | 41 | 2476 (56) | 2504 (55) | 1 |
| Non-steroidal anti-inflammatory drug | 892 (19) | 4347 (19) | 1 | 871 (20) | 894 (20) | 0 |
| Oral hypoglycemic agent or insulin | 1403 (31) | 4221 (19) | 28 | 1320 (30) | 1328 (29) | 1 |
| Potassium-sparing diuretic | not reported | 1431 (6) | 20 | 512 (12) | 505 (11) | 1 |
| Prostatic hyperplasia medication | not reported | 1078 (5) | 7 | 277 (6) | 255 (6) | 3 |
| Proton pump inhibitor | 1651 (36) | 6878 (30) | 12 | 1588 (36) | 1548 (34) | 3 |
| Statin | 2174 (47) | 9087 (40) | 15 | 2085 (47) | 2075 (46) | 2 |
| Number of unique drug identification numbers | | | | | | |
| Mean (standard deviation) | 6 (6) | 3 (5) | 54 | 6 (6) | 6 (6) | 0 |
| Median (interquartile range) | 5(0-10) | 3 (0-10) | | 5 (0-10) | 5 (0-10) | |
| Number of unique drug names | | | | | | |
| Mean (standard deviation) | 6 (6) | 3 (4) | 54 | 5 (5) | 5 (5) | 0 |
| Median (interquartile range) | 5 (0-10) | 3 (0-9) | | 5 (0-9) | 5 (0-9) | |
| | | | | | | |
| Pre-ED baseline kidney function¹ | | | | | | |

| | | | | | | |
|---|---------------|---------------|----|---------------|---------------|-----------------|
| Baseline serum creatinine in mg/dL | | | | | | |
| Mean (standard deviation) | 1.1 (0.6) | 0.9 (0.3) | 11 | 1.1 (0.6) | 1.1 (0.6) | 1 |
| Median (interquartile range) | 1.0 (0.8-1.3) | 0.9 (0.7-1.0) | | 1.0 (0.8-1.2) | 1.0 (0.8-1.2) | |
| Days serum creatinine measurement taken prior to ED visit | | | | | | |
| Mean (standard deviation) | 133 (102) | 137 (103) | 4 | 133 (102) | 134 (103) | 0 |
| Median (interquartile range) | 106 (44-207) | 114 (46-215) | | 107 (45-209) | 106 (43-210) | |
| Proportion with pre-ED serum creatinine ≤0.3mg/dL | not reported | 1309 (3) | 6 | 263 (4) | 264 (4) | 0 |
| Baseline eGFR in ml/min/1.73m ² | | | | | | |
| ≥60 | 3919 (62) | 35924 (83) | 48 | 3904 (63) | 3904 (63) | 0 |
| 45 to <60 | not reported | 4836 (11) | 17 | 1054 (17) | 1054 (17) | 0 |
| 30 to <45 | not reported | 2022 (5) | 31 | 803 (13) | 803 (13) | 0 |
| 15 to <30 | not reported | 570 (1) | 28 | 367 (6) | 367 (6) | 0 |
| <15, but not on dialysis | not reported | 70 (0.2) | 13 | 60 (1) | 60 (1) | 0 |
| Albumin-to-creatinine ratio in mg/g | | | | | | |
| <30 | not reported | 7404 (17) | 3 | 999 (16) | 964 (16) | 1 |
| 30 to <300 | not reported | 978 (2) | 12 | 267 (4) | 228 (4) | 3 |
| ≥300 | not reported | 1828 (4) | 9 | 382 (6) | 399 (6) | 1 |
| No measurement | 4657 (73.4) | 33212 (77) | 7 | 999 (16) | 964 (16) | 1 |
| CKD risk category ^m | | | | | | |
| Low risk | not reported | 6393 (15) | 10 | 721 (12) | 679 (11) | 2 |
| Moderate risk | not reported | 1436 (3) | 8 | 304 (5) | 296 (5) | 0 |
| High risk | not reported | 1910 (4) | 7 | 377 (6) | 391 (6) | 1 |
| Very high risk | not reported | 988 (2) | 34 | 578 (9) | 570 (9) | 0 |
| | | | | | | |
| ED visit laboratory characteristics | | | | | | |
| Serum creatinine in mg/dL | | | | | | |
| Mean (standard deviation) | 4.2 (0.6) | 4.0 (0.5) | 33 | 4.2 (0.6) | 4.0 (0.5) | 21 |
| Median (interquartile range) | 4.1 (3.8-4.5) | 3.9 (3.7-4.2) | | 4.0 (3.8-4.5) | 4.0 (3.7-4.3) | |
| Serum potassium in mEq/L | | | | | | |
| Mean (standard deviation) | 137 (5) | 138 (4) | 20 | 138 (5) | 138 (4) | 10 ⁿ |
| Median (interquartile range) | 138 (135-140) | 139 (137-141) | | 138 (136-140) | 139 (136-140) | |
| Serum sodium in mEq/L | | | | | | |
| Mean (standard deviation) | 6012 (95) | | | 5860 (95) | | |
| Median (interquartile range) | 290 (5) | | | 286 (5) | | |

| | | | | | | |
|---|--------------|------------|----|-----------|-----------|-----------------|
| AKI severity | 44 (0.7) | | | 42 (0.7) | | |
| | | | | | | |
| Previous health care utilization^o | | | | | | |
| Number of ED visits in the previous 30 days | | | | | | |
| 0 | 5232 (82) | 39677 (91) | 27 | 5127 (83) | 5352 (87) | 10 ^p |
| 1 | not reported | 1445 (3) | 7 | 302 (5) | 204 (3) | 8 |
| 2 | not reported | 775 (2) | 12 | 227 (4) | 135 (2) | 9 |
| ≥3 | not reported | 1525 (4) | 23 | 532 (9) | 497 (8) | 2 |
| Number of ED visits in the previous 31 to 365 days | | | | | | |
| 0 | 3836 (60) | 29542 (68) | 16 | 3750 (61) | 3853 (62) | 3 |
| 1 | not reported | 7928 (18) | 1 | 1152 (19) | 1154 (19) | 0 |
| 2 | not reported | 3138 (7) | 8 | 590 (10) | 559 (9) | 2 |
| ≥3 | not reported | 2814 (7) | 17 | 696 (11) | 622 (10) | 4 |
| Number of hospitalizations in the previous 30 days | | | | | | |
| 0 | 5865 (92) | 41001 (94) | 8 | 5728 (93) | 5759 (93) | 2 |
| 1 | not reported | 1707 (4) | 1 | 260 (4) | 252 (4) | 1 |
| 2 | not reported | 449 (1) | 8 | 120 (2) | 105 (2) | 2 |
| ≥3 | not reported | 265 (0.6) | 8 | 80 (1) | 72 (1) | 1 |
| Number of hospitalizations in the previous 31 to 365 days | | | | | | |
| 0 | 4894 (77) | 37494 (86) | 24 | 4813 (78) | 4798 (78) | 1 |
| 1 | not reported | 4592 (11) | 13 | 906 (15) | 986 (16) | 4 |
| 2 | not reported | 953 (2) | 15 | 296 (5) | 254 (4) | 3 |
| ≥3 | not reported | 383 (0.9) | 15 | 173 (3) | 150 (2) | 3 |
| Family physician visit | | | | | | |
| 0 | not reported | 939 (2) | 5 | 93 (2) | 90 (2) | 0 |
| 1-2 | not reported | 3999 (9) | 14 | 354 (6) | 333 (5) | 1 |
| 3-4 | not reported | 6646 (15) | 17 | 611 (10) | 649 (11) | 2 |
| 5-6 | 862 (14) | 7422 (17) | 10 | 854 (14) | 832 (14) | 1 |
| 7-8 | 735 (12) | 6165 (14) | 8 | 724 (12) | 799 (13) | 4 |
| 9-10 | not reported | 4736 (11) | 0 | 680 (11) | 683 (11) | 0 |
| ≥11 | 2990 (47) | 13515 (31) | 33 | 2872 (46) | 2802 (45) | 2 |
| General internist visit | | | | | | |

| | | | | | | |
|---|--------------|------------|----|-----------|-----------|---|
| 0 | 4876 (77) | 36803 (85) | 20 | 4781 (77) | 4768 (77) | 0 |
| 1 | 1148 (18) | 5726 (13) | 14 | 1107 (18) | 1152 (19) | 2 |
| 2 | 252 (4) | 768 (2) | 13 | 235 (4) | 216 (4) | 2 |
| ≥3 | 70 (1) | 125 (0.3) | 10 | 65 (1) | 52 (0.8) | 3 |
| Nephrology visit | | | | | | |
| 0 | 6060 (96) | 42861 (99) | 19 | 5928 (96) | 5979 (97) | 4 |
| 1 | 183 (3) | 396 (0.9) | 14 | 169 (3) | 131 (2) | 4 |
| 2 | 32 (0.5) | 52 (0.1) | 7 | 26 (0.4) | 22 (0.4) | 0 |
| ≥3 | 71 (1) | 113 (0.3) | 10 | 65 (1) | 56 (0.9) | 2 |
| Urology visit | | | | | | |
| 0 | 5214 (82) | 38337 (88) | 17 | 5085 (82) | 5142 (83) | 2 |
| 1 | 361 (6) | 1801 (4) | 7 | 353 (6) | 305 (5) | 4 |
| 2 | 305 (5) | 1354 (3) | 9 | 297 (5) | 280 (5) | 1 |
| ≥3 | 466 (7) | 1930 (4) | 12 | 453 (7) | 461 (7) | 0 |
| Imaging and investigations | | | | | | |
| Abdominal ultrasound ^q | 1530 (24) | 8291 (19) | 12 | 1480 (24) | 1465 (24) | 0 |
| Cardiac stress test | not reported | 5584 (13) | 7 | 948 (15) | 929 (15) | 1 |
| CT with contrast | not reported | 636 (2) | 10 | 172 (3) | 175 (3) | 0 |
| Coronary angiogram or revascularization | not reported | 702 (2) | 5 | 144 (2) | 135 (2) | 1 |
| Echocardiogram | not reported | 5204 (12) | 17 | 1077 (17) | 1004 (16) | 3 |
| Intervention for kidney stones ^r | not reported | 270 (0.6) | 6 | 77 (1) | 79 (1) | 1 |
| ED and hospital characteristics | | | | | | |
| Institution ^s | | | | | | |
| 1 | 1754 (28) | 13190 (30) | 6 | 1724 (28) | 1679 (27) | 2 |
| 2 | 1482 (23) | 11867 (27) | 9 | 1448 (23) | 1445 (23) | 0 |
| 3 | not reported | 3128 (7) | 11 | 626 (10) | 629 (10) | 0 |
| 4 | not reported | 2967 (7) | 2 | 456 (7) | 469 (8) | 1 |
| 5 | not reported | 1108 (3) | 1 | 156 (3) | 154 (3) | 0 |
| 6 | not reported | 262 (0.6) | 1 | 42 (0.7) | 41 (0.7) | 0 |
| 7 | not reported | 3143 (7) | 9 | 587 (10) | 579 (9) | 0 |
| 8 | not reported | 1583 (4) | 2 | 242 (4) | 250 (4) | 1 |
| 9 | not reported | 1651 (4) | 8 | 337 (5) | 327 (5) | 0 |
| 10 | not reported | 2883 (7) | 3 | 369 (6) | 382 (6) | 1 |

| | | | | | | |
|--|---------------|---------------|----|---------------|---------------|---|
| 11 | not reported | 1174 (3) | 2 | 145 (2) | 158 (3) | 2 |
| 12 | not reported | 271 (0.6) | 0 | 34 (0.5) | 48 (0.8) | 4 |
| 13 | not reported | 195 (0.4) | 0 | 22 (0.4) | 27 (0.4) | 0 |
| ED and hospital activity | | | | | | |
| Standardized number of registrations in the last 12h ^t | | | | | | |
| Mean (standard deviation) | 1.1 (0.3) | 1.1 (0.3) | 14 | 1.1 (0.3) | 1.1 (0.3) | 0 |
| Median (interquartile range) | 1.1 (0.9-1.3) | 1.0 (0.8-1.3) | | 1.1 (0.9-1.3) | 1.1 (0.9-1.3) | |
| Standardized number of hospital admissions in the last 24h ^u | | | | | | |
| Mean (standard deviation) | 1.1 (0.3) | 1.1 (0.3) | 3 | 1.1 (0.3) | 1.1 (0.3) | 3 |
| Median (interquartile range) | 1.1 (0.8-1.3) | 1.1 (0.8-1.2) | | 1.1 (0.8-1.3) | 1.1 (0.8-1.3) | |
| Standardized number of hospital inpatient discharges in the last 24 ^v | | | | | | |
| Mean (standard deviation) | 1.1 (0.4) | 1.1 (0.3) | 3 | 1.1 (0.3) | 1.1 (0.4) | 0 |
| Median (interquartile range) | 1.1 (0.8-1.2) | 1.1 (0.8-1.3) | | 1.1 (0.8-1.2) | 1.1 (0.8-1.2) | |
| Proportion of ED registrations resulting in Hospitalization ^w | 47% | 49% | 4 | 47% | 47% | 0 |
| ED seasonal and time characteristics | | | | | | |
| Weekday (Monday-Friday) | | | | | | |
| 0700 to <1700 | 2463 (53) | 18436 (58) | 11 | 2399 (53) | 2462 (54) | 2 |
| 1700 to <2400 | 1624 (35) | 8768 (28) | 16 | 1578 (35) | 1513 (33) | 4 |
| 0000 to <0700 | not reported | 4471 (14) | 6 | 549 (12) | 599 (13) | 3 |
| Weekend (Saturday-Sunday) | | | | | | |
| 0700 to <1700 | not reported | 6560 (56) | 11 | 842 (51) | 852 (53) | 4 |
| 1700 to <2400 | not reported | 3318 (28) | 16 | 588 (35) | 547 (34) | 3 |
| 0000 to <0700 | not reported | 1869 (16) | 6 | 232 (14) | 215 (13) | 2 |
| Season ^x | | | | | | |
| Fall | 1502 (24) | 11053 (26) | 4 | 1475 (24) | 1469 (24) | 0 |
| Winter | 1446 (23) | 9991 (23) | 1 | 1412 (23) | 1421 (23) | 0 |
| Spring | 1635 (26) | 11008 (25) | 1 | 1585 (26) | 1545 (25) | 1 |
| Summer | 1763 (28) | 11370 (26) | 4 | 1716 (28) | 1753 (28) | 1 |
| ED physician training | | | | | | |
| Emergency Medicine | 4642 (73) | 33336 (77) | 9 | 4542 (73) | 4541 (73) | 0 |
| Family Medicine | 1338 (21) | 7563 (17) | 9 | 1289 (21) | 1304 (21) | 1 |

| | | | | | | |
|---|--------------|------------|----|------------|-----------|---|
| Other | not reported | 2523 (6) | 0 | 357 (6) | 343 (6) | 1 |
| ED patient acuity and wait times | | | | | | |
| Canadian Triage Acuity Scale ^y | | | | | | |
| 1 and 2 | 1321 (21) | 9072 (21) | 0 | 1294 (21) | 1290 (21) | 0 |
| 3 | 3797 (60) | 25241 (58) | 4 | 3693 (60) | 3736 (60) | 1 |
| 4 and 5 | 1228 (19) | 9108 (21) | 4 | 1201 (19) | 1162 (19) | 2 |
| Time (in hours) waiting for physician assessment, mean (standard deviation) | | | | | | |
| Canadian Triage Acuity Scale 1 and 2 | 0.6 (0.8) | 0.6 (0.9) | 6 | 0.60 (0.8) | 0.6 (0.8) | 1 |
| Canadian Triage Acuity Scale 3 | 1.3 (1.3) | 1.4 (1.3) | 5 | 1.31 (1.3) | 1.3 (1.2) | 2 |
| Canadian Triage Acuity Scale 4 and 5 | 1.6 (1.4) | 1.8 (1.6) | 14 | 1.57 (1.4) | 1.6 (1.4) | 4 |
| 90% percentile ED length of stay, in hours | | | | | | |
| Canadian Triage Acuity Scale 1 and 2 | 9 | 8 | | 9 | 8 | |
| Canadian Triage Acuity Scale 3 | 8 | 8 | | 9 | 8 | |
| Canadian Triage Acuity Scale 4 and 5 | 8 | 8 | | 8 | 8 | |

Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; ED, emergency department; eGFR, estimated glomerular filtration rate.

To convert serum creatinine from traditional units (mg/dL) to SI units (µmol/L), multiply by 88.42.

^a Reported as n (%) unless otherwise noted. To comply with privacy regulations for minimizing the chance of patient re-identification, numbers of patients were suppressed in the case of five or fewer patients. The total number of patients was not reported if there were other calculations that could result in the re-identification of five or fewer patients.

^b Pharmacy forward sortation area refers to a region in Ontario represented by the first three letters of the postal code. This variable describes the number and proportion of individuals who live in the same region as the pharmacy that provided them with prescription medications.

^c Look-back window for co-morbidities was five years unless otherwise noted.

^d Does not include angina.

^e Major cancers include the following tissues/organs: lung/bronchi, colon/rectum, breast, pancreas, prostate, leukemia, non-Hodgkin lymphoma, liver, ovaries, and esophagus.

^f Look-back window for Charlson co-morbidity Index was two years.

^g The Aggregated Diagnosis Groups point score, derived from the John Hopkins Adjusted Clinical Groups system, score is a weighted measure of health care utilization as a proxy measure for co-morbidity and accounts for the duration of condition, severity of condition, diagnostic certainty, etiology of the condition, and specialty care involvement. The higher Aggregated Diagnosis Groups score, the greater the co-morbidity. Individuals with an Aggregated Diagnosis Groups score of 0 to 2 reflect low health care costs with no prior hospitalizations; 3 to 5, high health care costs but no prior hospitalizations; 6 or more, high health care costs and at least one prior hospitalization.

^h Look-back window for medication utilization was 120 days.

ⁱ Patients in long-term care can only be identified from the Ontario Drug Benefits database.

^j Percentages reported are based on the number of Ontario Drug Benefits eligible patients.

^k Does not include acetylsalicylic acid.

^l Pre-ED visit look-back window: 7 to 365 days.

^m Risk categories derived from the 2012 Kidney Diseases: Improving Global Outcomes clinical practice guidelines for CKD. Urine dipstick and urine protein values were converted to an estimate albumin-to-creatinine ratio.²

ⁿ Standardized difference 9.97%.

^o Look-back window for health care utilization was 365 days unless otherwise noted.

^p Standardized difference 10.001%.

^q Not specific for the assessment of kidneys.

^r Urological procedures included extracorporeal shockwave lithotripsy, percutaneous nephrolithotomy, or ureteroscopic lithotripsy with stone removal.

^s For privacy considerations, numbers of patients with AKI by ED disposition were not identified by individual hospital institution.

^t Standardized to the mean number of registrations that occurred in the last 12-hour period over the last 14 days.

^u Standardized to the mean number of hospital admissions that occurred in the last 24-hour period over the last 14 days.

^v Standardized to the mean number of hospital discharges that occurred in the last 24-hour period over the last 14 days.

^w Proportion of registrations resulting in hospitalization standardized to each ED/hospital institution's number of registrations occurring in the last 24 hours.

^x Fall: September 21 to December 20; Winter: December 21 to March 20; Spring: March 21 to June 20; Summer: June 21 to September 20.

^y Patients with a Canadian Triage Acuity Scale of 1 or 2 need to be seen immediately 98% of the time or within 15 minutes 95% of the time, respectively.

Patients with a Canadian Triage Acuity Scale of 3 or 4 need to be seen within 30 minutes 90% of the time or 60 minutes 85% of the time, respectively.

Patients with a Canadian Triage Acuity Scale of 5 need to be seen within 120 minutes 80% of the time.

References for Supplementary Content

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl.* 2012;2(2):1-138.
2. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl.* 2013;3(1):4-4.
3. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol.* 2008;61(4):344-349.
4. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. *Can J Clin Pharmacol.* 2003;10(2):67-71.
5. Goel V, Williams J, Anderson G, Blackstien-Hirsch P, Fooks C, Naylor D. *Patterns of Health Care in Ontario, 2nd Edition.* 1996.
6. Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. *J Am Coll Cardiol.* 1996;27(6):1335-1342.
7. Wodchis W, Bushmeneva K, Nikitovic M, McKillop I. Guidelines on person level cost using administrative databases in Ontario. 2013.